Viracta Therapeutics, Inc.

We are excited to announce positive data from the Phase 2 NAVAL-1 Trial and provide an update on the Nana-val clinical program. Listen to our NAVAL-1 update webcast here: https://lnkd.in/gbJ2MUmV Full news release can be found here: https://lnkd.in/ghAfBGbp

Did you know...? 40-65% of all peripheral T-cell lymphoma (PTCL) cases are associated with the Epstein-Barr Virus (EBV). EBV-positive PTCL cases are typically faster-progressing and more aggressive than those not associated with EBV. #EBV #lymphomaawareness

Planning to attend #PPLC2024? Check out our poster detailing topline results from Stage 1 of the NAVAL-1 trial in patients with R/R EBV-positive PTCL! #PPLC24 #lymphoma #PTCL

Today on #NationalCancerSurvivorsDay, we’re celebrating the resilience and strength of lymphoma survivors. The Lymphoma Research Foundation powers groundbreaking survivorship research and provides resources and support every step of the way, from the moment of diagnosis through treatment and beyond. Join us today to honor our community of survivors and thrivers: https://ow.ly/tSGf50S4qsn

We're supporting World Blood Cancer Day! 

We are thrilled to announce that Mike Faerm has joined Viracta as our Chief Financial Officer. Mike is a seasoned biotech executive with more than 25 years of experience in life sciences companies, equity research and investment banking. Please join us in welcoming him to #TeamViracta! https://lnkd.in/eGRCzc6a

We are excited to announce positive topline Nana-val results from Stage 1 of the NAVAL-1 trial in patients with R/R EBV+ PTCL.   Here are the key highlights: 🔹 Patients with R/R EBV+ PTCL have a very poor prognosis, worse than those with EBV- disease, yet there are presently no EBV-targeted treatment options available 🔹Patients in the Nana-val treatment arm achieved clinically meaningful anti-tumor responses with an overall response rate of 50% and a complete response rate of 20% in the intent-to-treat population. 🔹 Nana-val demonstrated substantially greater efficacy than nanatinostat monotherapy, further validating its ‘Kick and Kill’ mechanism of action. 🔹 Nana-val was generally well tolerated, most common treatment-related adverse events were primarily mild to moderate in severity, and generally manageable or reversible. Read the full press release: https://lnkd.in/gNviCGhz #viractatherapeutics #NAVAL1Trial #ebv #EBVPositivePTCL #PrecisionOncology #ClinicalTrialResults

Did you know the Epstein-Barr virus (EBV) is associated with 75-95% of all Nasopharyngeal carcinoma (NPC) cases?   #HeadandNeckCancerAwarenessMonth #NPC #EBV #DefeatCancer 

Today marks the 60th anniversary of the discovery of the Epstein-Barr Virus (EBV), one of the most common viral infection in humans and the first virus to be identified as oncogenic in humans. In addition to cancer, EBV is also linked as a major driver of MS and other autoimmune diseases.

Epstein-Barr Virus at 60. The 1964 discovery of Epstein–Barr virus shed light on factors that contribute to human cancer. Subsequent studies set the stage for finding ways to diagnose and treat cancer, and revealed how immune defences control viral infection. #EBV #viruses #cancer #immunology #lymphoma #multiplesclerosis